Hervé Tilly Selected Research

Hervé Tilly Research Topics

Disease

42	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2022 - 01/2002
34	Lymphoma (Lymphomas) 03/2022 - 05/2002
28	Neoplasms (Cancer) 01/2022 - 02/2004
23	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 07/2008
21	B-Cell Lymphoma (Lymphoma, B Cell) 03/2022 - 06/2005
12	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2022 - 12/2003
9	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 12/2007
6	Infections 07/2022 - 05/2015
6	Disease Progression 01/2021 - 07/2008
6	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 01/2014
6	Neutropenia 01/2018 - 11/2005
5	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 09/2010
5	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2018 - 09/2010
4	Residual Neoplasm 01/2021 - 01/2016
3	Fatigue 01/2020 - 01/2019
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2017 - 09/2010
2	Fever (Fevers) 08/2018 - 06/2005
2	Febrile Neutropenia 01/2018 - 05/2015
2	Sarcopenia 07/2014 - 04/2014
2	Hematologic Neoplasms (Hematological Malignancy) 11/2013 - 01/2005
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2013 - 08/2011
1	Venous Thrombosis (Deep-Vein Thrombosis) 07/2022
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021
1	Leukemia 01/2021
1	Philadelphia Chromosome 01/2021
1	Leukopenia 01/2020
1	Obesity 01/2019
1	Candidiasis (Moniliasis) 08/2018

Drug/Important Bio-Agent (IBA)

50	Rituximab (Mabthera)FDA Link 03/2022 - 01/2002
17	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2002
17	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2002
16	Prednisone (Sone)FDA LinkGeneric 01/2022 - 01/2002
15	Vincristine (Oncovin)FDA LinkGeneric 01/2022 - 01/2002
9	Lenalidomide (CC 5013)FDA Link 01/2022 - 08/2017
8	obinutuzumabIBA 01/2022 - 05/2012
8	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 10/2012
6	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 01/2012
6	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 09/2010
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 11/2013
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2016
5	Cell-Free Nucleic AcidsIBA 10/2020 - 07/2015
5	Monoclonal AntibodiesIBA 08/2013 - 01/2002
4	polatuzumab vedotinIBA 01/2022 - 01/2019
4	Etoposide (VP 16)FDA LinkGeneric 11/2015 - 09/2010
3	Gemcitabine FDA Link 01/2022 - 11/2013
3	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2016
3	Bendamustine Hydrochloride FDA Link 01/2021 - 12/2016
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020 - 04/2015
3	Biological ProductsIBA 07/2019 - 01/2016
3	Melphalan (Alkeran)FDA LinkGeneric 11/2015 - 04/2011
3	Bleomycin (Blenoxane)FDA LinkGeneric 07/2015 - 03/2005
2	Circulating Tumor DNAIBA 01/2022 - 01/2021
2	Indicators and Reagents (Reagents)IBA 01/2021 - 11/2017
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 11/2020
2	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 11/2020
2	Pharmaceutical PreparationsIBA 01/2021 - 06/2016
2	tazemetostatIBA 11/2020 - 01/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 11/2020 - 02/2011
2	AnthracyclinesIBA 12/2017 - 01/2012
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2017 - 09/2013
2	AntigensIBA 01/2017 - 01/2002
2	Brentuximab VedotinIBA 01/2017 - 03/2016
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2016 - 06/2005
2	Histone Deacetylase InhibitorsIBA 01/2016 - 04/2015
2	Exportin 1 ProteinIBA 01/2016 - 01/2016
2	Carmustine (FIVB)FDA Link 11/2015 - 12/2014
2	Vindesine (Vindesin)IBA 12/2014 - 03/2005
2	Yttrium-90IBA 12/2014 - 04/2011
2	ibritumomab tiuxetan (Zevalin)FDA Link 12/2014 - 04/2011
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2013 - 11/2005
2	InterferonsIBA 08/2011 - 07/2008
2	Methotrexate (Mexate)FDA LinkGeneric 02/2011 - 09/2010
1	PlatinumIBA 03/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 03/2022
1	ibrutinibIBA 03/2022
1	SaltsIBA 03/2022
1	NivolumabIBA 01/2022
1	Arginine (L-Arginine)FDA Link 04/2021
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 04/2021
1	FluorineIBA 04/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Histones (Histone)IBA 01/2020
1	TransferasesIBA 01/2020
1	pinatuzumab vedotinIBA 05/2019
1	Busulfan (Busulfex)FDA Link 08/2018

Therapy/Procedure

35	Therapeutics 10/2022 - 05/2002
34	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
15	Stem Cell Transplantation 03/2022 - 05/2002
4	Induction Chemotherapy 11/2020 - 12/2003
4	Transplantation 11/2020 - 05/2007
3	Ligation 01/2020 - 04/2015
3	Salvage Therapy 01/2016 - 07/2008
3	BEAM regimen 11/2015 - 04/2011
2	Autologous Transplantation 01/2021 - 08/2011
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 01/2017
2	VAP-cyclo protocol 05/2013 - 01/2002
2	Radiotherapy 03/2007 - 03/2005
2	Chemoradiotherapy 03/2007 - 03/2005
1	Vascular Access Devices (Arterial Line) 07/2022
1	Catheters 07/2022